Scienture Holdings Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.23next fiscal year
Monitoring Framework
Key Performance Indicators
ARBLI™ (SCN-102) Net Revenue Quarterly56.3KTarget: Sequential quarterly growth
REZENOPY™ (Naloxone HCl) Commercial Launch Status QuarterlyTarget: Commercial launch in mid-July 2026
Cash and Cash Equivalents Quarterly3.5MTarget: Sufficient capital to fund operations and commercialization
Watch Items
- Going Concern Risk and Capital RunwayTrigger: Cash balance falling below $2.0 million without additional non-dilutive or dilutive financingAction: Evaluate further debt drawdowns, equity raises, or strategic partnerships to extend runway.
- Nasdaq Minimum Bid Price ComplianceTrigger: Failure to maintain a closing bid price of at least $1.00 per shareAction: Monitor Nasdaq compliance extensions and evaluate a potential reverse stock split if necessary.
- REZENOPY™ Formulary and Commercial RolloutTrigger: Delays in the mid-July 2026 commercial launch or slow initial sales uptakeAction: Leverage the existing commercial infrastructure and payer relationships established through ARBLI™.
Research as of 20 Jun 2026